IC
ERNA icon

Inverness Counsel’s Eterna Therapeutics ERNA Stock Holding History

Inverness Counsel’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$299K Hold
161
– – 0.02% 157
2022
Q2 		$627K Hold
161
– – 0.04% 104
2022
Q1 		$2.48M Hold
161
– – 0.11% 60
2021
Q4 		$5.05M Buy
161
+159
+7,950% +$8.65M 0.19% 53
2021
Q3 		$127K Hold
2
– – ﹤0.01% 171
2021
Q2 		$240K Buy
+2
New +$288K 0.01% 157

Other funds holding ERNA

LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Inverness Counsel's ERNA Position: Q3 2022 in Review

Inverness Counsel held its Eterna Therapeutics (ERNA) position steady in Q3 2022 at 161 shares worth $299K. The position accounts for 0.02% of the portfolio, ranked #157.

Inverness Counsel first reported a position in ERNA in Q2 2021 and has held it in 6 quarters since. The position peaked at $5.05M in Q4 2021. 31 funds tracked by Wall St. Rank hold ERNA as of Q3 2022.

  • Inverness Counsel held 161 shares of Eterna Therapeutics worth $299K as of Q3 2022.
  • Inverness Counsel left its Eterna Therapeutics share count unchanged in Q3 2022.
  • Eterna Therapeutics made up 0.02% of Inverness Counsel's portfolio in Q3 2022, its #157 holding.
  • Inverness Counsel first reported a position in Eterna Therapeutics in Q2 2021 and has held it in 6 quarters since.
  • Inverness Counsel's Eterna Therapeutics position peaked at $5.05M in Q4 2021.
  • 31 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q3 2022.

Based on Inverness Counsel's 13F filing for Q3 2022, filed 26 Oct 2022.